secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvation Bio Inc. (NUVB)
CIK:        0001811063
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0001193125-24-138263
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvation Bio Q1 net loss $14.8M; completes AnHeart acquisition; cash $597M
--------------------------------------------------------------------------

- Net loss of $14.8M ($0.07 per share) vs $21.7M ($0.10) in Q1 2023.
- Cash, equivalents and marketable securities of $597.0M as of March 31, 2024.
- Acquisition of AnHeart Therapeutics closed in April 2024, transforming Nuvation into late-stage global oncology company.
- Appointed Colleen Sjogren as Chief Commercial Officer; first patient dosed in Phase 1/2 study of NUV-1511 DDC.
- Updated taletrectinib Phase 2 TRUST-I data to be presented at ASCO 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/0001193125-24-138263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1811063/000119312524138263/d693344d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-138263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer